Healthcare ❯ Pharmaceuticals ❯ Drug Development ❯ Clinical Trials

Obesity Treatments

Zealand Plunges as Roche Obesity Drug Posts 10.7% Weight Loss With Placebo‑Like Tolerability

Underwhelming efficacy has investors questioning differentiation, dose response, Phase 3 upside.

Viking Therapeutics' Obesity Drug Moves Into Phase 3 as Investors Weigh Upside

Lancet Phase 3 Trial Shows Oral GLP-1 Orforglipron Aids Weight Loss and Diabetes Control

Novo Nordisk Raises Metsera Bid to $10 Billion, Outpacing Pfizer’s $8.1 Billion Counter